Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jihad Abialmouna

Rheumatology West Amherst, NY Medical Doctor

NPI 1396793782 CMS profile 63383

2800 Sweet Home Rd, Suite#6, West Amherst, NY 14228

Open in the dashboard

General payments

$18,153

1,051 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jihad Abialmouna of West Amherst, NY is reported in the CMS Open Payments database as having received $18,153 across 1,051 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,136 106
2024 General $2,142 101
2023 General $2,186 131
2022 General $3,147 170
2021 General $2,818 181
2020 General $2,950 169
2019 General $2,774 193

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jihad Abialmouna
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Jihad Abialmouna were reported at $2,136. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Jihad Abialmouna Rheumatology median Middle half National median
2019 $2,774 $744 $153–$2,687 $163
2020 $2,950 $462 $98–$2,027 $114
2021 $2,818 $531 $101–$2,153 $132
2022 $3,147 $627 $125–$2,303 $149
2023 $2,186 $741 $145–$2,524 $160
2024 $2,142 $830 $166–$2,660 $164
2025 $2,136 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $2,111 157 payments
  2. AbbVie, Inc. $2,073 124 payments
  3. AstraZeneca Pharmaceuticals LP $1,954 78 payments
  4. Janssen Biotech, Inc. $1,540 158 payments
  5. Amgen Inc. $1,352 75 payments
  6. GlaxoSmithKline, LLC. $1,137 65 payments
  7. Lilly USA, LLC $996 58 payments
  8. Mallinckrodt Hospital Products Inc. $939 45 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $834 44 payments
  10. UCB, Inc. $744 35 payments
  11. Other $4,473 212 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $17,766 1,042 payments
  2. Education $387 9 payments
Products named General payments · program years 2019–2025
  1. SIMPONI ARIA $1,172 145 payments
  2. XELJANZ $1,025 88 payments
  3. RINVOQ $1,001 50 payments
  4. ACTHAR $939 45 payments
  5. SAPHNELO $905 33 payments
  6. TREMFYA $760 56 payments
  7. BENLYSTA $738 41 payments
  8. STELARA $711 91 payments
  9. Cimzia $593 29 payments
  10. AIRSUPRA $510 12 payments
  11. Other $15,505 889 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 134 drugs

Part D claims

7,800

Median for Internal Medicine: 777

Drug cost

$1,746,848

Median for Internal Medicine: $73,373

Branded share of claims

23.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xeljanz Xr Tofacitinib Citrate Brand 49 $363,043
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 42 $319,450
Rinvoq Upadacitinib Brand 34 $221,839
Humira Pen Adalimumab Brand 21 $142,426
Benlysta Belimumab Brand 22 $113,212
Enbrel Sureclick Etanercept Brand 14 $95,980
Jardiance Empagliflozin Brand 48 $62,208
Eliquis Apixaban Brand 48 $43,784
Janumet Sitagliptin Phos/Metformin Hcl Brand 28 $38,916
Ozempic Semaglutide Brand 30 $38,212

The 10 drugs with the highest cost, of 134 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$30,568

Of which drugs: $231

Medicare patients

159

Average age 72

Services billed

808

99 women, 60 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 33%
Ischemic heart disease 28%
Chronic kidney disease 25%
COPD 25%
Osteoporosis 19%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 48 308 $209
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 19 28 $22

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
$359 — —
RINVOQ
$266 34 —
BENLYSTA
$146 22 —
XELJANZ
$132 49 —
SAPHNELO
$121 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

1,051 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record